
    
      A phase 1 open-label, multi-centre, single-arm trial to evaluate the safety and
      pharmacokinetics (including MUsT) of twice daily topical application of delgocitinib cream
      for 8 weeks in adults, adolescents, and children with moderate to severe atopic dermatitis
    
  